Cancer research laboratory tests can now be done using micro-physiological systems mimicking human physiology, allowing ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

The inflammatory tumor microenvironment (TME) is a complex network of cancer, immune, and stromal cells interacting through cytokines and growth factors to drive tumor growth, angiogenesis, and immune ...

Cancer immunotherapy is a type of cancer treatment that harnesses the immune system to fight cancer cells. The treatment ...

The tumor microenvironment (TME) consists of mediators surrounding a tumor, including diverse cell types, blood vessels, and other cellular components. Certain elements of the TME can benefit patients ...

Researchers sought to determine whether zanubrutinib combined with rituximab and lenalidomide would improve remission rates in older adults with newly diagnosed DLBCL.

Large BIDMC-led study maps immune cells in myeloma tumors, improving risk prediction beyond genetics and helping identify ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

The field of regulated cell death has undergone a transformative shift with the discovery of novel modalities beyond apoptosis, such as ferroptosis, which ...

This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis.

Existing oncology therapeutics are either so specific they can target only part of a tumor, or so generalized they kill healthy tissue. A new “Tumor Activated Therapy™” in development at the small ...